Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Ogura M, et al. Among authors: hatake k. J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10. J Clin Oncol. 2014. PMID: 24616310 Clinical Trial.
Does rituximab really induce hepatitis C virus reactivation?
Ennishi D, Yokoyama M, Terui Y, Takeuchi K, Ikeda K, Tanimoto M, Hatake K. Ennishi D, et al. Among authors: hatake k. J Clin Oncol. 2008 Oct 1;26(28):4695-6; author reply 4696. doi: 10.1200/JCO.2008.18.7609. J Clin Oncol. 2008. PMID: 18824720 No abstract available.
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K. Terui Y, et al. Among authors: hatake k. Clin Cancer Res. 2009 Apr 1;15(7):2523-30. doi: 10.1158/1078-0432.CCR-08-1403. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276251
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.
Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, Suzuki T, Kobayashi Y, Watanabe T, Azuma T, Mori M, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Ono C, Ohata J. Ogura M, et al. Among authors: hatake k. Cancer Sci. 2010 Aug;101(8):1840-5. doi: 10.1111/j.1349-7006.2010.01601.x. Epub 2010 Apr 23. Cancer Sci. 2010. PMID: 20491780 Free article. Clinical Trial.
Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.
Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Nakagawa Y, et al. Among authors: hatake k. J Infect Chemother. 2011 Feb;17(1):58-67. doi: 10.1007/s10156-010-0075-3. Epub 2010 Jul 3. J Infect Chemother. 2011. PMID: 20602137 Clinical Trial.
Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan.
Nishimori H, Takahashi S, Kiura K, Ennishi D, Kobayashi T, Sano K, Shinozaki E, Yokoyama M, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Nishimura S, Takeuchi K, Ishikawa Y, Oguchi M, Tanimoto M, Hatake K. Nishimori H, et al. Among authors: hatake k. Acta Med Okayama. 2010 Oct;64(5):285-91. doi: 10.18926/AMO/40503. Acta Med Okayama. 2010. PMID: 20975761 Free article.
470 results